Geron Corp (GERN)

[Bandito]

Analysts at WBB Securities maintain their "strong buy" rating on Geron Corporation Inc (GERN.NAS). The 12-month target price has been raised to $16.50.

In a research note published this morning, the analysts mention that the company and its scientific collaborators have announced success in a lab test, which is likely to result in the development of a hESC product for repairing human hearts damaged by myocardial infarction. Geron is now going to test the mixture of proteins and stem cells in larger animals and the results are expected by mid-2008, the analysts say. Geron’s share price does not reflect an acquisition premium, although the company could become a target due to its unique position in both hESC and Telomerase, WBB Securities adds